Frailty: A global measure of the multisystem impact of COPD by Gale, Nichola et al.
Original paper
Frailty: A global measure of the
multisystem impact of COPD
Nichola S Gale1 , Ali M Albarrati1,2,
Margaret M Munnery3, Ruth E Hubbard4,
Ruth Tal-Singer5, John R Cockcroft3 and Dennis J Shale1
Abstract
Chronic obstructive pulmonary disease (COPD) is a multisystem disease that resembles the accumulation of
multiple impairments seen in aging. A comprehensive geriatric assessment (CGA) captures multisystem
deficits, from which a frailty index (FI) can be derived. We hypothesized that patients with COPD would be
frailer than a comparator group free from respiratory disease. In this cross-sectional analysis, the CGA
questionnaire was completed and used to derive an FI in 520 patients diagnosed with COPD and 150
comparators. All subjects were assessed for lung function, body composition, 6-minute walking distance
(6MWD), and handgrip strength. Patients completed validated questionnaires on health-related quality of
life and respiratory symptoms. Patients and comparators were similar in age, gender, and body mass index,
but patients had a greater mean+ SD FI 0.16+ 0.08 than comparators 0.05+ 0.03. In patients, a stepwise
linear regression 6MWD (b ¼ 0.43), number of comorbidities (b ¼ 0.38), handgrip (b ¼ 0.11), and
number of exacerbations (b ¼ 0.11) were predictors of frailty (all p < 0.01). This large study suggests patients
with COPD are frailer than comparators. The FI derived from the CGA captures the deterioration of multiple
systems in COPD and provides an overview of impairments, which may identify individuals at increased risk of
morbidity and mortality in COPD.
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Introduction
Chronic obstructive pulmonary disease (COPD) is one
of the few major chronic conditions increasing in pre-
valence. The defining feature of COPD is impaired lung
function, but extra-pulmonary comorbidities contribute
to reduced health-related quality of life (HRQoL),
increased morbidity, and mortality risk.1,2 Quantifying
multimorbidity is challenging as current routine clinical
assessments do not take account of comorbidities. How-
ever, a scoring system based on body mass index (BMI),
airflow obstruction, dyspnea and exercise tolerance
(BODE index) along with comorbidities predicted mor-
tality risk over a 4-year period.1
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Comorbidities represent deficits in individual phy-
siological systems and resemble the accumulation of
deficits in natural aging, which may result in frailty.3,4
Frailty is associated with aging and manifests as fail-
ure to respond to external stresses and maintain home-
ostasis.5 Frailty better predicts adverse outcomes than
age, independent of coexisting medical conditions.6
The similarities between the accumulation of deficits
in aging and multiple comorbidities in COPD sug-
gests that frailty is likely to occur in COPD and be
related to increased morbidity.3 Studies in a range of
general populations and COPD patients have pro-
duced an inconsistent prevalence of frailty in
COPD7,8 ranging from 10% frail and 51% intermedi-
ate frail, in the Rotterdam study9 to 57.8% frail in
physician diagnosed COPD,10 and 25.6% in patients
referred for pulmonary rehabilitation.8 A recent study
reported 21% frailty in a Japanese COPD cohort.11 In
addition to various populations studied, there were
differences in study design, methods to assess frailty,
and lack of appropriate population controls.12,13
There are a number of validated tools to assess
frailty.3,12,13 The key ones in current use include the
following. (1) The phenotypic definition based on the
presence of 3 of five deficits including walking
speed, handgrip strength, activity levels, weight loss,
and exhaustion,3 which has been criticized for not
grading or specifying degrees of frailty. (2) To consider
frailty as a multidimensional, risk state quantified by
the number, rather than the nature of physiological
deficits.3,6,13 Using a widely validated questionnaire
to capture information on health status and function,
the comprehensive geriatric assessment (CGA) and a
frailty index (FI-CGA) can be derived.14 In many
populations, this operationalized approach to defining
and quantifying frailty has demonstrated that accumu-
lated deficits are a stronger predictor of mortality than
chronological age.13 In geriatric medicine, the FI-CGA
is used clinically to assess the multisystem impacts of
aging and indicate premature aging.6,14
Although there have been other studies of frailty in
COPD, to our knowledge, this is the first to explore
and report frailty using the CGA, in a well-
characterized population of community-dwelling
patients with COPD, along with a group of compara-
tors similar in age and sex from the same community.
We hypothesized that frailty occurs in COPD based
on the FI-CGA assessment and that patients would be
more frail than comparators independent of age,
which may indicate an accelerated and premature
aging process in COPD.
Methods
Study design and participants
This cross-sectional analysis included community-
based patients with COPD, confirmed by spirometry
at entry, and comparators (current or ex-smokers free
from respiratory disease). Participants were drawn
from the prospective Assessment of Risk in Chronic
Airways Disease Evaluation (ARCADE) study (Clin-
ical Trials.gov, NCT01656421)15 and included all par-
ticipants who completed the CGA. All participants
were clinically stable, not having received or oral cor-
ticosteroids in the previous 4 weeks prior to recruit-
ment. Exclusions included inflammatory disease such
as rheumatoid arthritis, oral maintenance corticoster-
oids, inflammatory bowel syndrome, and long-term
oxygen therapy. The exclusions were to study a sample
of patients representative of the general COPD popu-
lation, without significant impairment due to recent
exacerbation or use of long-term oxygen
therapy (LTOT).
Participants were recruited from respiratory outpa-
tient clinics, pulmonary rehabilitation, smoking ces-
sation referrals, general practice databases, and
previous participants in respiratory research at Cardiff
University. Comparators were recruited, based on
being a current or past smoker, from primary and
smoking cessation clinics, as well as past volunteers
in research and partners of patients with COPD, in an
attempt to standardize socioeconomic differences. All
participants gave written informed consent and the
study had approval from the South East Wales
Research Ethics Committee.
Frailty and questionnaires relating to COPD
All participants completed a modified version of the
CGA questionnaire,4 specific to community-
dwelling individuals. The CGA collects data on
self-rated health, psychological well-being, mobi-
lity, function, nutritional status, medications, and
comorbidities that are coded to reflect deficits
(Online Supplemental 1). In community-dwelling
participants of the Canadian Study of Health and
Aging, the FI-CGA was a valid and reliable means
of quantifying health status, stratifying patients’ risk
of institutionalization and death.16 The CGA was
modified by removal of the components specific to
hospital admission and data were collected by a
researcher-administered questionnaire that took less
than 10 minutes to complete. The FI-CGA was
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calculated by dividing the total number of CGA def-
icits by the maximum possible score of 61.
Patients with COPD completed the St. George’s
respiratory questionnaire (SGRQ), a validated
disease-specific measure of HRQoL, scores ranging
from 0 to 100, with high scores representing worse
status,17 and the COPD assessment test (CAT), scored
0–40 with high scores indicating more symptoms.18
Patients reported the number of respiratory exacerba-
tions (defined as requirement for antibiotic or oral
corticosteroid therapy) per year19 and the number of
previously diagnosed comorbidities in patients and
comparators were also self-reported using a standar-
dized questionnaire that was verified by researcher at
the clinical assessment. Infrequent exacerbators were
defined as <2 in the previous year, while frequent
exacerbators as 2. Breathlessness was recorded
using the modified Medical Research Council
(mMRC) dyspnea scale.
Lung function
All participants performed spirometry (Vitalograph
Alpha, Vitalograph Ltd), to determine forced expira-
tory volume in one second (FEV1), forced vital capac-
ity (FVC), and the FEV1:FVC ratio. A diagnosis of
COPD was confirmed as post bronchodilator spirome-
try FEV1:FVC <0.70.
19 Patients were classified
according to the combined assessment, Global initia-
tive for chronic Obstructive Lung Disease (GOLD)
A–D based on the CAT score.19
Body composition and physical performance
Weight and body composition were measured barefoot
in lightweight indoor clothing; fat percentage, fat-free
mass (FFM), and the BMI (kg/m2) were determined
using a segmental bioelectrical impedance analyzer
(BC418 Tanita Corp, Tokyo). The FFM index (FFMI)
was expressed as a height-squared ratio FFMI (kg/m2).
A stretch resistant tape measure was used to measure
waist and hip circumference.
All participants completed the 6-minute walking
distance (6MWD) test with pretest resting heart rate
and oxygen saturation by pulse oximetry.20 Mean max-
imum handgrip strength, twice with each hand, was
determined using a hand dynamometer (Takei, Japan).
Inflammation
High sensitivity C-reactive protein (HsCRP) and
fibrinogen were determined in venous blood by
standard procedures (University Hospital of Wales,
Biochemistry).
Data analysis
Data analysis was performed using the Statistical
Package for the Social Sciences (SPSS, Chicago,
USA), version 18.0. Results are presented as mean
+ SD, geometric mean for log10 transformed data
and median, interquartile range (IQR). Analyses
included the independent t test, Wilcoxon test, Pear-
son’s (r) or Spearman’s (rs) correlation, and stepwise
multiple regression.
Results
Participant characteristics
The FI was greater in the patients 0.16 + 0.08 than
the comparators 0.05 + 0.03 (p < 0.001). Patients
also had poorer lung function FEV1, FVC and
FEV1/FVC, greater smoking history, larger waist cir-
cumference, lower handgrip, and 6MWD, as well as
greater inflammation (HsCRPlog10 and fibrinogen).
However, patients and comparators were similar in
age, gender, BMI, and body composition (Table 1).
Female patients had greater FI 0.17 + 0.09 than
males 0.14+ 0.09 (p < 0.001) and female comparators
had greater FI 0.06 + 0.04 than males 0.04 +0.03.
Frailty and characteristics of COPD
Based on the upper 90th centile FI for comparators
(0.09) as a cutoff for frailty, 76% of the patients and
13% of comparators were frail. However, using the
upper 50% confidence interval of the age adjusted cut-
off for frailty from the Survey of Health, Ageing and
Retirement in Europe (SHARE) cohort (a large general,
unselected, age-related European population), 28%
(n¼ 143) of patients and 0% of comparators were frail.
Frail patients (according to SHARE) were younger,
had poorer lung function, greater BMI, waist, and fat
percentage as well as poorer handgrip and 6MWD
compared to non-frail patients. Frail patients also had
greater inflammation (interleukin (IL)-6 and HsCRP)
and more exacerbations, symptoms (CAT) and poorer
quality of life (SGRQ), all p < 0.05 (Table 1).
Medical history
Patients with COPD had more comorbidities and
reported more medications than comparators (p <
0.05). The most commonly reported comorbidity in
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both patients and comparators was hypertension and
hypercholesterolemia.
Frail patients with COPD had more comorbidities
including a greater proportion reporting cardiovascu-
lar disorders as well as diabetes, osteoporosis and
osteoarthritis, and more medications than non-frail
patients with COPD (p < 0.05; Table 2). This
remained after adjustment of age and the number of
comorbidities: frail 0.18 +0.05 versus non-frail 0.14
+0.4 (p < 0.05). Of the patients, frequent exacerba-
tors (>2/year), n¼ 310, had a greater mean FI 0.19+
0.09 than infrequent exacerbations (0–1/year), n ¼
210, 0.15+ 0.08, and both had a greater FI than that
of the comparator group, 0.05 + 0.04 (p < 0.001).
Using the SHARE cutoff for frailty for each
decade,21 mean FI and the percentage of frail patients
differed across age categories (Figure 1(a)), MRC
dyspnea (Figure 1(b)), GOLD 1–4 (Figure 1(c)), and
classified according to the GOLD 1–4 and using the
combined assessment of COPD A–D using the CAT
score (Figure 1(d); all p < 0.05). Age and gender did
not differ across the classifications and only the
number of comorbidities differed across the GOLD
categories A–D.
When adjusted statistically for the number of comor-
bidities, the number of patients classified as frail
according to SHARE reduced to n¼ 75. The proportion
of frail patients no longer differed across the mMRC,
GOLD 1–4, or GOLD A–D categories (p > 0.05).
Relationships between FI and participant
characteristics
In COPD, FI was inversely related to FEV1%, hand-
grip, and 6MWD. Measures of body composition
(BMI, waist circumference, and fat percentage) and
inflammation (HsCRP and fibrinogen) were directly
related to FI, along with disease specific question-
naires as well as the number of comorbidities and
exacerbations per year (all p < 0.01; Table 3).
In patients, a stepwise linear regression with the FI
as a dependent variable, FEV1%, BMI, handgrip,
6MWD, number of exacerbations per year, number
of comorbidities and fibrinogenlog10, as were included
Table 1. Subject characteristics.a
Comparator
(n ¼ 150) COPD (n ¼ 520) p
COPD frail
(n ¼ 143)
COPD non-frail
(n ¼ 377) p
CGA total 2.25 (1.25–4.0) 8.75 (5.75–12.75) <0.001 15.25 (13.25–17.5) 6.75 (4.25–9.25) <0.001
FI 0.05 + 0.03 0.16 + 0.08 <0.001 0.26 + 0.06 0.11 + 0.05 <0.001
Gender, male:female 76:74 270:250 0.451 61:82 209:168 0.009
Age (years) 65.0 + 7.4 66.1 + 7.6 0.109 63.7 + 8.2 67.1 + 7.1 <0.001
FEV1/FVC (L) 0.78 + 0.05 0.53 + 0.11 <0.001 0.52 + 0.10 0.53 + 0.11 0.278
FEV1 (% predicted) 105+ 14 58 + 19 <0.001 53 + 18 60 + 19 <0.001
FVC (% predicted) 109+ 15 87 + 21 <0.001 81 + 21 89 + 20 <0.001
Smoking (pack years) 22+ 18 41 + 25 <0.001 42 + 26 40 + 25 0.487
BMI (kg/m2) 28.1 + 4.1 28.0 + 5.5 0.951 29 + 7 28 + 5 0.038
Waist circumference (cm) 95+ 10 100 + 15.0 0.001 102 + 16 99 + 15 0.015
Hip circumference (cm) 105+ 9 104 + 11 0.25 106 + 13 104+ 11 0.041
Fat% 33.3 + 7.8 34.1 + 8.4 0.345 36 + 10 34 + 8 0.026
FFMI (kg/m2) 18.5 + 2.3 18.1 + 2.6 0.097 18.1 + 2.7 18.1 + 2.6 0.980
Handgrip (kg) 31.3 + 10.3 27.1 + 9.7 <0.001 23.3 + 9.5 28.5 + 9.4 <0.001
6MWD (m) 502+ 85 335 + 125 <0.001 244 + 113 366+ 113 <0.001
Fibrinogen (g/L)b 3.08 + 1.25 3.51 + 1.31 <0.001 3.6 + 1.3 3.4 + 1.3 0.028
HsCRP (mg/ml)b 1.76 + 3.18 3.49 + 2.89 <0.001 4.1 + 1.6 3.2 + 2.8 0.021
mMRC d 2 (1–3) d 3 (2–4) 2 (1–3) <0.001
SGRQ totalc d 53 (36–68) d 69 (57–78) 45 (31–58) <0.001
CAT scorec d 21 (14–27) d 28 (24–32) 18 (13–23) <0.001
6MWD: 6-minute walk distance; BMI: body mass index; CAT: COPD assessment test; CGA: comprehensive geriatric assessment; FEV1:
forced expiratory volume in 1 second; FFMI: fat-free mass index; FVC: forced vital capacity; HsCRP: high sensitivity C-reactive protein;
mMRC: modified Medical Research Council; SGRQ: St George’s respiratory questionnaire; IQR: interquartile range.
aAll data mean+ SD or median (IQR); p < 0.05 significant difference between groups.
bGeometric mean.
cn ¼ 500.
dNot assessed.
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as independent variables, based on the results of corre-
lations between CGA and the independent variables.
This produced a significant model which explained
51% of the variance of frailty. 6MWD (b ¼ 0.43),
was the primary predictor, followed by number of
comorbidities (b¼0.38), handgrip (b¼ 0.11), and
number of exacerbations (b ¼ 0.11; all p < 0.01). In
comparators, number of comorbidities (b ¼ 0.432),
6MWD (b ¼ 2.33), and BMI (b ¼ 0.22) explained
38% of the variance of frailty (p < 0.01).
In frail patients, the FI was related to BMI
(r ¼ 0.12), fat mass (r ¼ 0.13), waist (r ¼ 0.24), HGS
(r ¼ 0.26), 6MWD (r ¼ 0.46), number of exacer-
bations (rs ¼ 0.14), SGRQ (rs ¼ 0.48), and CAT
(rs ¼ 0.45) (all p < 0.05), but not inflammation.
Discussion
In this study, patients with COPD were frailer than a
comparator group, similar in age, gender and BMI but
free from respiratory disease, and as demonstrated by
their greater number of deficits measured as part of
the CGA and higher FI score. In our female patients
and comparators, the FI was greater than in their
counterpart males, a similar relationship to that
reported in the general population. The mean FI of
females with COPD was greater than the reported FI
of 0.15 for women over 65 years of age from general
populations.22–24
The finding that 28% of our patients were frail
based on the SHARE cohort is similar to a recent
UK study in patients referred for pulmonary rehabili-
tation which reported that 26% of their patients were
frail using a hybrid of Fried’s criteria.8 A recent study
reported a prevalence of 21% frailty in patients with
COPD using the Kihon Checklist.11 These studies are
lower than a UK population study where the reported
prevalence of frailty was 57.8% in 70 COPD patients
diagnosed on the basis of symptoms rather an objec-
tive measure of airways obstruction.10 Unlike the
Table 2. Comorbidities, exacerbations, and medications in patients and comparators.a
Comparator,
n ¼ 150 COPD, n ¼ 520 p COPD non-frail, 377 COPD frail, 143 p
No. of comorbidities 2 (1–3) 3 (2–4) <0.001 2 (1–3) 1 (0–2) <0.001
Hypertension 34 245 <0.001 166 79 0.030
Angina 0 61 <0.001 35 26 0.050
Myocardial infarction 0 46 0.002 26 20 0.011
Atrial fibrillation 5 42 0.018 30 12 0.871
Heart failure 0 19 0.025 15 4 0.521
Other heart diseasec 4 40 0.045 21 20 0.001
Transient ischemic attack 2 36 0.009 18 18 0.002
Hypercholesterolemia 41 237 <0.001 157 80 0.003
Diabetes mellitus 0 67 <0.001 38 29 0.002
Osteoporosis 9 87 0.001 46 41 <0.001
Peripheral vascular disease 3 19 0.317 8 11 0.003
Osteoarthritis 40 177 0.089 113 64 0.001
No. of exacerbations/year* b 2 (1–3) b 3 (2–3) 1 (1–3) <0.001
No. of medications 2 (0–3) 5 (3–8) <0.001 5 (3–7) 8 (5–11) <0.001
ACE inhibitors 9 115 <0.001 77 38 0.130
Angiotensin receptor blockers 2 44 0.002 31 13 0.749
Calcium channel blockers 8 114 <0.001 78 36 0.267
Beta blockers 5 42 0.047 31 11 0.844
Diuretics 11 109 <0.001 79 30 0.992
Anticoagulants 2 27 0.041 21 6 0.528
Statins 27 192 <0.001 128 64 0.022
Bisphosphonates 5 72 <0.001 37 35 <0.001
Respiratory inhalersd 0 419 <0.001 294 120 0.134
ACE: angiotensin-converting enzyme.
aAll data mean+ SD or median interquartile range (IQR); p < 0.05 significant difference between groups.
bNot assessed.
cOther heart disease: arrhythmia, enlarged heart, heart murmur, valve disease, vessel disease.
dInhalers: bronchodilators, inhaled corticosteroids, anti-muscarinic, alone or in combination
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latter study, our study population was unselected
based on physician defined COPD with mandatory
demonstration of airways obstruction at the time of
entry to the ARCADE study15 and hence provided a
wider spectrum of disease severity and comorbidities
which might account for the variation. Comparisons
between this study and other studies725, are difficult
due to different assessments of frailty and older study
populations, which may not represent a typical COPD
population. We used the validated CGA tool, which
allowed our participants to be compared with other
populations and has shown to be a predictor of out-
comes than chronological age, disability, and the need
for health-care support.6,13, Based on our own cutoff
from frailty from our comparator group, the percent-
age of frail patients was found high (76%). This may
be a result of low levels of frailty in comparators due
to rigorous exclusion criteria and self-selection of
volunteers for the study.
Using the SHARE cutoff, frail patients had reduced
physical capacity, greater systemic inflammation,
worse symptoms, and quality of life. Hence, frailty
in COPD appears to have impacts and background
mechanisms similar to those in natural aging where
it is part of the spectrum of multimorbidity. There is
likely to be two aspects of COPD interwoven with
each other and frailty; the physiological processes of
natural aging occurring in all individuals and the
impact of COPD and its associated exacerbations and
greater comorbidity levels.26 Comorbidities in COPD
are an important factor in the overall morbidity and
mortality1 and their interaction may be related to the-
greater systemic inflammatory state in aging – inflam-
maging – and the inflammatory surges during
exacerbations superimposed on the background
inflammatory state in COPD.2 This speculation is
supported by the association between frailty and the
number of comorbidities and number of exacerbations
per year seen in this study. This potentially provides a
testable explanation of premature aging in COPD.
Although, frailty in COPD was unrelated to chron-
ological age, the proportion of frail patients differed
across the age categories. Interestingly, patients aged
50–59 had greatest FI and the largest proportion of
frail patients which could potentially be explained by
a survival bias where frail patients fail to reach older
age. In addition, frailty differed according to the dis-
ease severity classified by GOLD, in mild disease
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Figure 1. Mean frailty index (FI) and percentage of frail patients classified by (a) age categories, (b) Medical Research
Council (MRC) dyspnea score, (c) Global initiative for chronic Obstructive Lung Disease (GOLD) 1–4, and (d) GOLD
A–D (using the CAT score).
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(GOLD 1), 17% of patients were frail increasing to
34% frail in GOLD 3 and 4. Patients in GOLD cate-
gories B&D with more symptoms as measured by the
CAT score were frailer. These differences did not
remain when frailty was adjusted for the number of
comorbidities. This suggests that frailty may be as a
result of increasing deficits which may occur prema-
turely even in mild COPD.
Frailty associated with components of body com-
position, including BMI, fat percentage, and waist
circumference. The linear relationship with BMI con-
trasts with the U-shaped distribution reported in the
English Longitudinal Study of Ageing, but may be a
consequence of small numbers of individuals with a
low BMI.22 In both COPD and natural aging,
increases in fat and abdominal obesity have been
closely linked to impaired physical function.27
Increased fat mass and frailty in the older people have
also been linked to increased levels of circulating
inflammatory biomarkers.28 Circulating CRP, an indi-
cator of IL-6 activity, increases with age and has been
linked to frailty and truncal obesity, independent of
BMI, which may reflect the negative impact of
chronic low grade systemic inflammation, a feature
of COPD, on physical function and well-being.29
Hence, our findings suggest frailty in COPD is a mul-
tifactorial function perhaps resulting in reduced phys-
ical function and quality of life.
In the present study, frailty was predicted by phys-
ical function (6MWD and handgrip) and the number
of exacerbations and comorbidities. This aligns with
previous studies where the nonlinear association of
frailty with age, functional dependence, and chronic
disease has been established.3,4,6,12–14,30 Although
there are few specific studies in individual chronic
diseases, such as reported here, in the Women’s
Health and Aging Studies, the risk of frailty increased
with inflammatory comorbidities. This showed that
the combination of pulmonary disease with anemia
carried a risk ratio of 5.57 compared with comparator
participants who had fewer comorbidities.31 A further
study in this female cohort demonstrated that frailty
was related nonlinearly to the number of abnormal
physiological systems, which resembles the impact
of multiple comorbidities in COPD.12 Such physiolo-
gical deficits included loss of skeletal muscle mass
(sarcopenia) and function, with progressive loss of
capacity for physical activity, loss of bone mineral
density, increased systemic inflammation, reduction
in HRQoL, and increased cardiovascular morbidity
and mortality.22,32,33
Our patients with COPD were stable at the time of
recruitment but had higher levels of inflammation
(HsCRP and fibrinogen) than comparators; however,
the difference in fibrinogen between patients and
comparators was small. The higher, than expected,
levels of inflammation in comparators may be attrib-
uted to the age of the participants and potential pres-
ence of subclinical disease in some comparators
despite being free from occult respiratory, cardiovas-
cular disease, or inflammatory conditions.34 COPD is
characterized by low-grade inflammation; both CRP
and fibrinogen are acute phase proteins produced by
the liver and have been associated with disease sever-
ity in COPD. However, fibrinogen is thought to be a
more specific marker and has being associated with
increased risk of exacerbation, hospitalization, and
extra pulmonary manifestations.35 The reported asso-
ciations with frailty and aging, in many ways parallels
findings in COPD, where systemic inflammation may
be causal, compensatory, or an epi-phenomenon.
This accumulation of deficits in COPD resembled
the pattern of that occurring with aging healthy popu-
lations, potentially allowing the prediction of poor
Table 3. Relationship between FI and participant
characteristics.a
COPD p Comparators p
Age 0.16 0.715 0.124 0.132
FEV1% 0.189 <0.001 0.220 0.007
FEV1/FVC 0.052 0.233 0.120 0.143
Smoking pack years 0.050 0.258 0.014 0.870
BMI 0.227 <0.001 0.323 <0.001
Waist circumference 0.213 <0.001 0.278 0.001
Fat% 0.218 <0.001 0.366 <0.001
Handgrip 0.324 <0.001 0.185 0.024
6MWD 0.597 <0.001 0.360 <0.001
HsCRPlog10 0.158 <0.001 0.294 <0.001
Fibrinogen log10 0.181 <0.001 0.200 0.016
No. of comorbiditiesb 0.541 <0.001 0.473 <0.001
No. of exacerbation/
yearb
0.327 <0.001 — —
Dyspnea (mMRC)b 0.466 <0.001 — —
SGRQ totalb 0.615 <0.001 — —
CAT scoreb 0.594 <0.001 — —
6MWD: 6-minute walk distance; BMI: body mass index; CAT:
COPD assessment test; CGA: comprehensive geriatric assess-
ment; FEV1: forced expiratory volume in 1 second; FFMI: fat-
free mass index; FVC: forced vital capacity; HsCRP: high sensitivity
C-reactive protein; SGRQ: St George’s respiratory questionnaire;
FI: frailty index; mMRC: modified Medical Research Council;
COPD: chronic obstructive pulmonary disease.
ap < 0.05 significant correlation.
bSpearman’s rank correlation.
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outcomes such as increased risk of falls, hospitaliza-
tion, residential care, reduced HRQoL, disability, and
increased mortality.34,6,12–14,30 Although there are a
number of ways of determining frailty, the CGA has
the advantage of being a simple, rapid questionnaire
that is applicable for all health-care sectors.
Limitations of the study
As with the majority of cross-sectional studies, a
limitation of the findings is that they may be influ-
enced by bias, confounding, and lack of causality.
Although patients and comparators were similar,
they were not matched and there were differences
in the number of comorbidities between the groups.
This, however, reflects the multisystem nature of the
COPD inherent to the disease. The ARCADE study
was designed to describe a representative COPD
group and a comparator group rather than a true
controlled study. Frailty did not relate to age and
after adjustment for smoking history, frailty
remained elevated in COPD in line with Park’s study
where smoking was unrelated to frailty.10 A limita-
tion of the CGA questionnaire to determine frailty is
that it relies on patient recall; nevertheless, many of
the parameters could be verified by medical notes,
physical assessment, and carers.
Conclusion
Patients with COPD were frailer than a comparator
group of current or ex-smokers, independent of age.
Frailty was predicted by the number of comorbidities
and the number of exacerbations per year as well as
physical function. This study highlights the need to
take a global view of COPD to quantify the systemic
nature of the disease. The CGA is a quick, simple, and
inexpensive questionnaire that provides a global
assessment of COPD. The CGA may be a useful clin-
ical tool to highlight the multisystem deficits of
COPD, which could guide interventions, monitor dis-
ease processes, and improve patient care.
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